- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07736976
Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers
Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers: A Cross-Sectional Observational Study
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Hemophilia is an inherited bleeding disorder caused by deficiency of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B), resulting in recurrent bleeding episodes. Repeated musculoskeletal bleeding, particularly hemarthrosis, may lead to progressive joint damage, reduced physical activity, muscle weakness, and impaired functional performance. Therefore, objective assessment of physical function is important for monitoring functional limitations and planning appropriate rehabilitation strategies in individuals with hemophilia.
The 30-Second Sit-to-Stand Test (30STS) is a simple, practical, and reliable performance-based assessment used to evaluate lower extremity strength, endurance, and functional mobility. Although the test is widely used in different populations, evidence regarding 30STS performance in individuals with hemophilia is limited. Comparing functional performance between individuals with hemophilia and healthy peers may provide valuable information regarding the functional impact of hemophilia and may contribute to clinical assessment approaches.
The aim of this cross-sectional observational study is to compare 30STS performance between individuals with hemophilia and age-matched healthy controls. Additionally, the study aims to investigate the relationship between 30STS performance, joint health status, and activity level in individuals with hemophilia.
A total of 58 participants aged 18-35 years will be included in the study, consisting of 29 individuals diagnosed with hemophilia A or hemophilia B and 29 age-matched healthy controls. All participants will perform the 30STS. Demographic characteristics, including age, height, and body weight, will be recorded. For participants with hemophilia, additional clinical information including hemophilia type, disease severity, bleeding history, and prophylaxis status will be collected.
Joint health status of individuals with hemophilia will be evaluated using the Hemophilia Joint Health Score (HJHS), and functional activity level will be assessed using the Hemophilia Activities List (HAL). The results of the 30STS will be compared between groups, and associations between functional performance, joint health, and activity level will be analyzed within the hemophilia group.
The findings of this study may contribute to a better understanding of lower extremity functional performance in individuals with hemophilia and may provide clinically relevant information for functional evaluation and rehabilitation planning
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Tuğçe Poyraz İşleyen
- Numéro de téléphone: +905354467305
- E-mail: tugce.poyrazisleyen@bau.edu.tr
Lieux d'étude
-
-
Istanbul
-
Istanbul, Istanbul, Turquie (Türkiye), 34353
- Bahçeşehir University
-
Contact:
- tuğçe Poyraz İşleyen
- Numéro de téléphone: +90(212) 381 00 00
- E-mail: tugce.poyrazisleyen@bau.edu.tr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
Hemophilia Group:
- Diagnosis of hemophilia A or hemophilia B
- Age between 18 and 35 years
- Ability to walk independently
- Willingness to participate in the study voluntarily
Healthy Control Group:
- Age between 18 and 35 years
- No history of hemophilia or other bleeding disorders
- No history of lower extremity surgery or serious lower extremity injury within the previous 6 months
- No neurological, rheumatological, or severe orthopedic disorders
- Willingness to participate in the study voluntarily
Exclusion Criteria:
Hemophilia Group:
- Acute joint bleeding episode within the previous 3 months
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Hemophilia Group
Participants aged 18-35 years with a diagnosis of hemophilia A or hemophilia B.
|
|
Healthy Control Group
Age-matched healthy participants without hemophilia or other bleeding disorders.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
30-Second Sit-to-Stand Test Performance
Délai: Baseline assessment (single assessment visit)
|
The primary outcome of this study is the performance on the 30-Second Sit-to-Stand Test (30STS).
The test evaluates lower extremity functional performance by recording the number of correctly completed sit-to-stand repetitions within 30 seconds.
The test will be performed once under standardized conditions in both the hemophilia group and healthy control group.
Number of complete sit-to-stand repetitions performed from a standard chair within 30 seconds.
Scores range from 0 to no fixed maximum, with higher scores indicating better lower extremity functional performance and muscle endurance.
|
Baseline assessment (single assessment visit)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Joint Health Status Assessed by Hemophilia Joint Health Score (HJHS)
Délai: Baseline assessment (single assessment visit)
|
Joint health status will be assessed in participants with hemophilia using the Hemophilia Joint Health Score (HJHS).
The HJHS evaluates hemophilic arthropathy-related findings including swelling, muscle atrophy, crepitus, range of motion loss, and pain in target joints.
Total HJHS score ranges from 0 to 124; lower scores indicate better joint health and higher scores indicate greater joint impairment.
|
Baseline assessment (single assessment visit)
|
|
Hemophilia Activities List (HAL)
Délai: Baseline assessment (single assessment visit)
|
Functional activity level in participants with hemophilia will be assessed using the Hemophilia Activities List (HAL), a patient-reported outcome measure evaluating limitations in daily activities and participation.
The total score ranges from 0 to 100, with higher scores indicating better functional ability and fewer activity limitations.
|
Baseline assessment (single assessment visit)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Tığçe Poyraz İşleyen, Bahçeşehir University
Publications et liens utiles
Publications générales
- van Genderen FR, van Meeteren NL, van der Bom JG, Heijnen L, de Kleijn P, van den Berg HM, Helders PJ. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia. 2004 Sep;10(5):565-71. doi: 10.1111/j.1365-2516.2004.01016.x.
- Kuijlaars IAR, van der Net J, Feldman BM, Aspdahl M, Bladen M, de Boer W, Cuesta-Barriuso R, Matlary RED, Funk SM, Hilliard P, John JA, Kempton CL, de Kleijn P, Manco-Johnson M, Petrini P, Poonnoose P, St-Louis J, Thomas S, Timmer MA, Trakymiene SS, van Vlimmeren L, Fischer K. Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. Haemophilia. 2020 Nov;26(6):1072-1080. doi: 10.1111/hae.14180. Epub 2020 Oct 15.
- McKay MJ, Baldwin JN, Ferreira P, Simic M, Vanicek N, Burns J; 1000 Norms Project Consortium. Reference values for developing responsive functional outcome measures across the lifespan. Neurology. 2017 Apr 18;88(16):1512-1519. doi: 10.1212/WNL.0000000000003847. Epub 2017 Mar 22.
- Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020 Mar;105(3):545-553. doi: 10.3324/haematol.2019.232132. Epub 2020 Feb 14.
- Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, Walker I, Brooker M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia. 2012 May;18(3):e91-4. doi: 10.1111/j.1365-2516.2011.02588.x. Epub 2011 Jun 7.
- Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost. 2003 Jul;1(7):1349-55. doi: 10.1046/j.1538-7836.2003.00262.x.
- Peyvandi F, Bolton-Maggs PH, Batorova A, De Moerloose P. Rare bleeding disorders. Haemophilia. 2012 Jul;18 Suppl 4:148-53. doi: 10.1111/j.1365-2516.2012.02841.x.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies génétiques, innées
- Maladies hématologiques
- Troubles de la coagulation sanguine
- Troubles hémorragiques
- Maladies génétiques liées à l'X
- Troubles de la coagulation sanguine, héréditaires
- Troubles des protéines de la coagulation
- Maladies et anomalies congénitales, héréditaires et néonatales
- Maladies hémiques et lymphatiques
- Hémophilie A
- Hémophilie B
Autres numéros d'identification d'étude
- E-78097791-020-5767
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .